Neuronetics (STIM)
(Delayed Data from NSDQ)
$3.49 USD
-0.03 (-0.85%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.50 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
STIM 3.49 -0.03(-0.85%)
Will STIM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STIM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STIM
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
STIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
Other News for STIM
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics announces publication of findings in Brain Stimulation
Top 5 Health Care Stocks That May Plunge In March
Neuronetics Inc Shrinks Board Following Strategy Review